ClinicalTrials.gg
RecruitingNCT06959524Updated Oct 20, 2026

AGENT DCB STANCE: Safety and Effectiveness Study of AGENT Drug-Coated Balloon Compared to Standard of Care Percutaneous Coronary Intervention (PCI) Treatment for de Novo Coronary Lesions

An interventional study of Drug Eluting Balloon and Drug eluting stent in Coronary Arterial Disease (CAD) and de Novo Lesions in Native Coronary Arteries, sponsored by Boston Scientific Corporation. Recruiting at 71 sites in 9 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-20.

Sponsored by Boston Scientific Corporation · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Aug 2025; still recruiting 1 year 2 months later.
Updated Oct 20, 2026Site recruiting status changed3 sites addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
1,616
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

AGENT DCB STANCE is a prospective, multicenter, open-label, 1:1 randomized controlled study designed to assess the safety and effectiveness of a treatment strategy with the AGENT Drug-Coated Balloon compared to standard of care percutaneous coronary intervention (PCI) treatment with drug eluting stent (DES) and/or balloon angioplasty in patients with de novo coronary lesions.

Subjects must have a de novo target lesion located in a native coronary artery.

Read the detailed description

The study will also contain a PK sub study and an IVUS sub study.

02

Conditions studied

  • Coronary Arterial Disease (CAD)
  • de Novo Lesions in Native Coronary Arteries

Keywords

  • Drug Coated Balloon
  • de novo
  • 97279374
03

In context

Lead sponsor

Boston Scientific Corporation is the lead sponsor of 528 studies on the registry; 40 are open to participants now.

Of its 65 completed or terminated interventional studies of FDA-regulated products, 57 (88%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Clinical Inclusion Criteria:

  • Subject must be at least 18 years of age.
  • Subject (or legal guardian) understands the trial requirements and the treatment procedures and provides written before any trial-specific tests or procedures are performed.
  • Subject is eligible for percutaneous coronary intervention (PCI).
  • Subject is willing to comply with all protocol-required follow-up evaluation.
  • Women of must agree to use a reliable method of from the time of screening through 12 months after the index procedure.

Angiographic Inclusion Criteria:

  • Target lesion is a de novo lesion located in a native coronary artery.
  • Target lesion must have visually estimated stenosis > 50% and \< 100% in symptomatic subjects (>70% and \<100% in asymptomatic subjects) prior to lesion pre-dilation.
  • Target lesion must be successfully pre-dilated.
  • If a non-target lesion is treated, it must be treated first and must be deemed a success.

Clinical Exclusion Criteria:

  • Subject has other serious medical illness (e.g. cancer, congestive heart failure) that may reduce to less than 12 months.
  • Subject has current problems with substance abuse (e.g. alcohol, cocaine, heroin, etc.) as assessed by Investigator.
  • Subject has planned procedure that may cause non-compliance with the protocol or confound data interpretation.
  • Subject is participating in another drug or device clinical study that has not reached its primary endpoint.
  • Subject intends to participate in another investigational drug or device clinical study within 12 months after the index procedure.
  • Subject is a woman who is pregnant or nursing. A pregnancy test must be performed within 7 days prior to the index procedure, except for women who definitely do not have child-bearing potential.
  • Subject has known to be \< 30% within the last 12 months.
  • Subject had PCI or other coronary interventions within the last 3 days.
  • Subject has planned PCI or CABG after the index procedure.
  • Subject had STEMI or QWMI \<72h prior to the index procedure.
  • Subject presents with ACS and rising biomarkers, or ongoing chest pain or is hemodynamically unstable.
  • Subject has cardiogenic shock (SBP \< 80 mmHg requiring inotropes, IABP or fluid support).
  • Subject has history (within 6 months prior to the index procedure) of (NYHA) class III or IV heart failure.
  • Subject is considered not able to tolerate at least 30 seconds of coronary occlusion of the target lesion.
  • Subject has known allergy to paclitaxel or other components of the used medical devices.
  • Subject has known or to contrast dye that in the opinion of the investigator cannot be adequately pre-medicated.
  • Subject has intolerance to antiplatelet drugs, anticoagulants required for procedure.
  • Subject has count \< 100k/mm3 (risk of bleeding) or > 700k/mm3.
  • Subject with renal insufficiency (creatinine ≥2.0 mg/dl) or failure (dialysis dependent).
  • Subject has previous or planned (within 30 days) TAVR.
  • Previous cardiac transplant.

Angiographic Exclusion Criteria:

  • In-stent restenosis.
  • Target lesion is located within a saphenous vein or arterial graft.
  • Target lesion is a total occlusion or has evidence of thrombus present in the target vessel.
  • Target lesion is severely calcified by angiography or has > 270° calcium arc on intravascular imaging or requires atherectomy or requires intravascular lithotripsy.
  • Subject has unprotected left main coronary artery disease (>50% diameter stenosis) or three-vessel coronary disease requiring revascularization of all 3 vessels.
  • Subject with planned treatment of lesion involving aortic ostial location \<3 mm from aorta.
  • Target Lesion is in a previously jailed side branch.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1,616 participants (estimated)

Study arms

  • Experimental
    Small Vessel - Test

    Small vessel subjects treated with AGENT DCB

    Device: Drug Eluting Balloon

  • Active comparator
    Small Vessel - Control

    Small vessel subjects treated with drug eluting stent

    Device: Drug eluting stent

  • Experimental
    Bifurcation - Test

    Bifurcation subjects with side branches treated with AGENT DCB

    Device: Drug Eluting Balloon

  • Active comparator
    Bifurcation - Control

    Bifurcation subjects with side branches treated with drug eluting stent or plain old balloon angioplasty

    Device: Drug eluting stent · Procedure: Plain old balloon angioplasty

  • Experimental
    Long Lesion - Test

    Long lesion subjects treated with AGENT DCB

    Device: Drug Eluting Balloon

  • Active comparator
    Long Lesion - Control

    Long lesion subjects treated with drug eluting stent

    Device: Drug eluting stent

  • Experimental
    Overall - Test

    All subjects treated with AGENT DCB

    Device: Drug Eluting Balloon

  • Active comparator
    Overall - Control

    All subjects treated with standard of care drug eluting stent and/or POBA

    Device: Drug eluting stent · Procedure: Plain old balloon angioplasty

Interventions

  • DeviceDrug Eluting Balloon

    AGENT DCB

    Also known as: DCB

  • DeviceDrug eluting stent

    Any commercially available DES used for standard of care.

    Also known as: DES

  • ProcedurePlain old balloon angioplasty

    Bifurcation side branch - POBA

06

What researchers measure

Primary outcomes

  1. Target Lesion Failure (TLF) rate

    Target Lesion Failure (TLF) rate - defined as any ischemia-driven revascularization of the target lesion (TLR), myocardial infarction (MI, Q-wave and non-Q-wave) related to the target vessel, or cardiac death. The MI events include the Peri-Procedural MI (PPMI) according to the SCAI MI definition and the spontaneous MI according to the 4th Universal MI definition.

    Time frame: 12-Month

07

Study locations

69 of 71 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided — The data and study protocol for this clinical trial may be made available to other researchers in accordance with the Boston Scientific Data Sharing Policy (http://www.bostonscientific.com/en-US/data-sharing-requests.html)

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Aug 2025 (actual). Primary completion is estimated for Mar 2028, 31 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 28, 2025
First posted
May 6, 2025
StartActual
Aug 21, 2025
Primary completionEst.
Mar 2028
CompletionEst.
Mar 2032
Last update
Oct 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
3 sites added. 2 sites changed recruiting status (1 now withdrawn, 1 now recruiting)
Show 2 sites
  • MEDICLIN Herzzentrum Lahr · Lahr, GermanyRecruiting→Withdrawn
  • The Prince Charles Hospital · Chermside, AustraliaNot yet recruiting→Recruiting
Show 3 added (1 Japan, 1 United States, 1 South Korea)
  • Kitasato University Hospital · Sagamihara, Japan
  • Honor Health · Scottsdale, United States
  • Asan Medical Center · Seoul, South Korea
across 2 updates, Sep 29, 2026 – Oct 20, 2026
Site contacts
Changed at 3 sites. See the sites
Show 3 sites
  • MEDICLIN Herzzentrum Lahr · Lahr, GermanyContact removed K•••@mediclin.de · •••1330
  • Los Robles Hospital & Medical Center · Thousand Oaks, United StatesContact d•••@mednet.ucla.edu · •••3746→S•••@hcahealthcare.com · •••1111
  • The Prince Charles Hospital · Chermside, AustraliaContact •••4711→•••4711
across 2 updates, Sep 29, 2026 – Oct 20, 2026
Show all 2 updates
  1. Oct 20, 2026
    2 sites added. The Prince Charles Hospital is now Recruiting
    Show 2 added (1 United States, 1 South Korea)
    • Honor Health · Scottsdale, United States
    • Asan Medical Center · Seoul, South Korea
    Site contacts Changed at 2 sites. See the sites
    Show 2 sites
    • Los Robles Hospital & Medical Center · Thousand Oaks, United StatesContact d•••@mednet.ucla.edu · •••3746→S•••@hcahealthcare.com · •••1111
    • The Prince Charles Hospital · Chermside, AustraliaContact •••4711→•••4711
    + 1 other change: verification date
  2. Sep 29, 2026
    1 site added. MEDICLIN Herzzentrum Lahr is now Withdrawn
    Show site
    • Kitasato University Hospital · Sagamihara, Japan
    Site contacts Changed at 1 site. See the sites
    Show the site
    • MEDICLIN Herzzentrum Lahr · Lahr, GermanyContact removed K•••@mediclin.de · •••1330
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06959524
Responsible party
Sponsor
First posted
May 6, 2025
Start date
Aug 21, 2025
Primary completion
Mar 2028 (estimated)
Completion
Mar 2032 (estimated)
Last update
Oct 20, 2026

Study contacts

Beth Lawson
Contact
beth.lawson@bsci.com
508-683-6560
Kim Pena-Trast
Contact
kim.pena-trast@bsci.com
904-314-4269
David Kandzari
principal investigator · Piedmont Heart Institute
Margaret McEntegart
principal investigator · NYPH/CUIMC

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion